Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O43396
UPID:
TXNL1_HUMAN
Alternative names:
32 kDa thioredoxin-related protein
Alternative UPACC:
O43396
Background:
Thioredoxin-like protein 1, also known as the 32 kDa thioredoxin-related protein, plays a crucial role in cellular redox processes with a redox potential of about -250 mV. This protein is pivotal in maintaining a reduced environment within cells, which is essential for the proper functioning of various cellular processes.
Therapeutic significance:
Understanding the role of Thioredoxin-like protein 1 could open doors to potential therapeutic strategies. Its involvement in redox balance suggests its potential in targeting diseases where oxidative stress is a known contributor.